| CTNT 0.1608 -5.80% | ZSPC 0.0871 21.48% | ONFO 1.5 124.89% | MYSE 3.3 129.17% | NVDA 198.35 -0.26% | BITO 10.35 0.49% | TZA 5.43 -0.46% | TSLL 13.07 -1.73% | INTC 68.5 5.48% | CAPS 0.5345 -9.25% | HUBC 0.1833 -29.50% | DVLT 0.8375 19.63% | SOXS 20.28 -3.13% | TQQQ 56.43 1.40% | QBTS 21.505 3.34% | AGAE 0.5219 10.57% | HIMS 26.99 11.12% | IONQ 44.68 3.31% | DGNX 0.5556 -0.79% | GRAB 4.02 2.55% | SNAP 6.02 -0.33% | SOFI 19.03 1.28% | SMR 11.41 -2.56% | TSLA 388.9 -0.78% | ITP 0.2 -3.57% | BMNG 1.53 0.66% | SOXL 88.37 2.80% | AMD 278.26 7.80% | RGTI 19.45 1.78% | OPEN 5.27 9.34% | MDCX 0.3003 -0.60% | PLUG 2.86 -2.39% | MARA 11.55 10.32% | NVD 5.81 0.69% | AAL 12.27 0.82% | SQQQ 58.61 -1.40% | IMMP 0.5796 6.54% | HOOD 86.85 -0.54% | ONDS 10.2 1.69% | NVTS 12.37 20.57% | RMSG 2.55 42.46% | BYND 0.782 4.11% | NOK 10.29 3.00% | NFLX 107.79 0.07% | ORCL 178.46 5.09% | SPY 701.66 0.25% | SOUN 7.7 -1.91% | AAPL 263.4 -1.14% | PBM 5.87 103.82% | PLTR 142.76 0.43%

Raymond James Downgrades Weave on Timing of Catalysts and SMB Software Pressure

Raymond James downgraded Weave Communications (NYSE: WEAV) from Strong Buy to Outperform and lowered its price target to $10.00 from $12.00.

The firm said its longer-term thesis on Weave remained largely intact, but the rating change reflected the timing of expected catalysts and a more challenging environment for small and mid-sized business software companies. Raymond James noted that Weave continued to gain traction across several growth initiatives, including expansion into Specialty Medical, which had become its second-largest market by locations.

The analyst also pointed to progress in multi-office deployments, including a recently announced win covering more than 600 locations, and a growing pipeline for its AI receptionist and automation solution, TrueLark. Additional growth opportunities were seen through deeper integrations, improved product packaging, potential ARPC expansion via AI and payments offerings, and broader go-to-market partnerships.

While these initiatives were expected to take time to fully materialize, Raymond James said it still saw a path toward re-accelerating growth and a return to a more consistent beat-and-raise pattern. The firm added that although shares traded at just 2x its 2026 sales estimate, a full re-rating was unlikely until organic growth acceleration became more visible or the company demonstrated a clearer glide path toward long-term profitability.

Published on: January 6, 2026